Interferon-α is implicated in the transcriptional regulation of vascular endothelial growth factor

Journal of the National Cancer Institute

Volumn 95, Issue 6, 2003, Pages 420-421

  Tosato, Giovanna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOSINE; GUANINE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CHO CELL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL OBSERVATION; COLON CANCER; CONDYLOMA ACUMINATUM; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE INACTIVATION; GENE MAPPING; GENE MUTATION; GROWTH INHIBITION; GROWTH REGULATION; HAIRY CELL LEUKEMIA; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; KAPOSI SARCOMA; MELANOMA; MITOSIS; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REPORTER GENE; TRANSACTIVATION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0037454219     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.6.420     Document Type: Editorial

References (31)

1. Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73-85.
2. Tannock I. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumor. Br J Cancer 1968;22:258-73.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
5. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
6. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-9.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
9. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles-Gerte E, McDonnell T, et al. Angiogenic potential of prostate carcinoma cells over-expressing bcl-2. J Natl Cancer Inst 2001;93:208-13.
10. Phillips HS, Hains J, Leung DW, Ferrara N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 1990;127:965-7.
11. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-16.
12. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
13. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
14. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
15. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips HS, et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 1993;91:160-70.
16. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
17. Borgstrom, P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-9.
18. Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther 2001;299:1073-85.
19. Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001;7 Suppl 3:S134-8.
20. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma. growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
21. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1:193-202.
22. von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Öberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-48.
23. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516-8.
24. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-61.
25. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497-502.
26. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989;320:1197-200.
27. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med 1989;320:1211-2.
28. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995;92:4562-6.
29. Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM, et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001;3:154-64.
30. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
31. Dianzani F. Interferon treatments: how to use an endogenous system as a therapeutic agent. J Interferon Res 1992;Spec No:109-18.